UTR Therapeutics plans to initiate a Phase 1 trial of UTRxM1-18 in patients with advanced c-MYC–driven tumors pending regulatory approvals. The company is also exploring translational and commercial ...

Raymond James revealed in a note to clients on Tuesday that it has added Cogent Biosciences and Dime Community Bancshares to ...

The global tomato powder market, valued at USD 1.7 billion in 2025, is projected to reach nearly USD 2.3 billion by 2030, ...

Cambridge-based startup CuspAI, which has just unveiled $100 million funding from global investors, was named Business of the ...

The biotechnology sector is entering a period of rapid growth and meaningful innovation. Global biotech revenue is expected to expand at roughly 13 to 14% annually over the next decade, moving from ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, ...

Half Year ResultsNewron presents H1 2025 results and provides business update 16.09.2025 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Newron presents H1 2025 ...

Company's portfolio highlight clinical and real-world data on major depressive disorder, treatment-resistant depression and ...